A clinicohistopathological study of 12 cases of primary adenocarcinoma of the bladder diagnosed over an 11 year period is presented. Six of these were pure adenocarcinomas, while the remainder consisted of 2 adenocarcinoma with transitional malignant elements, 2 adenosquamous carcinomas and 2 mesonephric adenocarcinomas. The biological behaviour of these neoplasms was particularly aggressive: in none of the cases was the neoplasm limited to the bladder epithelium, but was generally seen to have infiltrated the muscular wall. Leaving aside the specific treatment carried out, the prognosis was in all patients poor and a complete clinical recovery was achieved for just 2 subjects. Except for one case, death was always directly attributable to bladder cancer, but as a result of obstructive and inflammatory diseases relating to the size and the degree of local infiltration of the tumor rather than metastatic spread.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[primary adenocarcinoma
4
adenocarcinoma bladder]
4
bladder] clinicohistopathological
4
clinicohistopathological study
4
study cases
4
cases primary
4
primary adenocarcinoma
4
adenocarcinoma bladder
4
bladder diagnosed
4
diagnosed year
4

Similar Publications

Background And Aims: Current gastric cancer (GC) screening modalities are invasive and expensive. Noninvasive screening for GC precursors with serum pepsinogen (PG) may improve early detection and prevention. Test characteristics of PG based on US prospective data was recently reported and used to study the cost-effectiveness of PG screening vs no screening in the US.

View Article and Find Full Text PDF

Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC).

View Article and Find Full Text PDF

Background And Aims: Hepatocellular carcinoma (HCC) recurrence was previously characterized into four types, and patients with progression/hyper-progression recurrence (type III-IV) have an extremely poor prognosis. However, the immune background of resectable HCC, particularly in patients who experience recurrence, remains underexplored. Therefore, this study aimed to describe the immune landscape of resectable HCC, especially postoperative type III-IV recurrent HCC, and explore potential immune-targeted anti-relapse strategies for treated populations.

View Article and Find Full Text PDF

Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.

Sci Rep

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Pathology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, China.

Delta-like protein (DLL3) is a novel therapeutic target. DLL3 expression in gastroenteropancreatic neuroendocrine tumors (GEP-NECs) is poorly understood, complicating the distinction between well-differentiated neuroendocrine tumors G3 (NET G3) and poorly differentiated NEC. DLL3 immunohistochemistry (IHC) was performed on 248 primary GEP-NECs, correlating with clinicopathological parameters, NE markers, PD-L1, Ki67 index, and prognosis.

View Article and Find Full Text PDF

A 36-year-old woman with a history of neck swelling was diagnosed with papillary thyroid carcinoma, a common but typically slow-growing thyroid cancer with a good prognosis. Despite frequent lymph node metastasis, mortality rates are low. This cancer can rarely spread to unusual areas like the axillary region.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!